- Home
- MIRA vs CVM Comparison
MIRA vs CVM Comparison
Compare MIRA & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- CVM
- Stock Information
- Founded
- MIRA 2020
- CVM 1983
- Country
- MIRA United States
- CVM United States
- Employees
- MIRA N/A
- CVM N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIRA Health Care
- CVM Health Care
- Exchange
- MIRA Nasdaq
- CVM Nasdaq
- Market Cap
- MIRA 19.5M
- CVM 18.1M
- IPO Year
- MIRA 2023
- CVM 1987
- Fundamental
- Price
- MIRA $1.42
- CVM $7.03
- Analyst Decision
- MIRA Strong Buy
- CVM
- Analyst Count
- MIRA 1
- CVM 0
- Target Price
- MIRA $17.00
- CVM N/A
- AVG Volume (30 Days)
- MIRA 907.1K
- CVM 599.1K
- Earning Date
- MIRA 08-15-2025
- CVM 08-18-2025
- Dividend Yield
- MIRA N/A
- CVM N/A
- EPS Growth
- MIRA N/A
- CVM N/A
- EPS
- MIRA N/A
- CVM N/A
- Revenue
- MIRA N/A
- CVM N/A
- Revenue This Year
- MIRA N/A
- CVM N/A
- Revenue Next Year
- MIRA N/A
- CVM N/A
- P/E Ratio
- MIRA N/A
- CVM N/A
- Revenue Growth
- MIRA N/A
- CVM N/A
- 52 Week Low
- MIRA $0.73
- CVM $1.98
- 52 Week High
- MIRA $2.70
- CVM $39.30
- Technical
- Relative Strength Index (RSI)
- MIRA 44.28
- CVM 53.67
- Support Level
- MIRA $1.35
- CVM $8.61
- Resistance Level
- MIRA $1.77
- CVM $9.43
- Average True Range (ATR)
- MIRA 0.10
- CVM 1.56
- MACD
- MIRA -0.05
- CVM -0.13
- Stochastic Oscillator
- MIRA 15.56
- CVM 36.17
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.